Enprofylline

Enprofylline (3-propylxanthine) is a xanthine derivative used in the treatment of asthma, which acts as a bronchodilator. It acts primarily as a competitive nonselective phosphodiesterase inhibitor with relatively little activity as a nonselective adenosine receptor antagonist.[1][2]

Enprofylline

Clinical data
ATC code	None
Identifiers
IUPAC name 3-Propyl-7H-purine-2,6-dione
CAS Number	41078-02-8
PubChem CID	1676
DrugBank	DB00824
ChemSpider	1613
UNII	DT7DT5E518
KEGG	D04006
ChEBI	CHEBI:126237
ChEMBL	ChEMBL279898
CompTox Dashboard (EPA)	DTXSID9045186
ECHA InfoCard	100.050.166
Chemical and physical data
Formula	C8H10N4O2
Molar mass	194.194 g·mol^−1
3D model (JSmol)	Interactive image
SMILES CCCn2c(=O)[nH]c(=O)c1nc[nH]c12
InChI InChI=1S/C8H10N4O2/c1-2-3-12-6-5(9-4-10-6)7(13)11-8(12)14/h4H,2-3H2,1H3,(H,9,10)(H,11,13,14) Key:SIQPXVQCUCHWDI-UHFFFAOYSA-N
(what is this?)  (verify)

References

1. Lunell E, Svedmyr N, Andersson KE, Persson CG (1982). "Effects of enprofylline, a xanthine lacking adenosine receptor antagonism, in patients with chronic obstructive lung disease". European Journal of Clinical Pharmacology. 22 (5): 395–402. doi:10.1007/bf00542541. PMID 6288396.
2. Laursen LC (December 1987). "Anti asthmatic effects and pharmacokinetics of enprofylline--a new xanthine derivate". Danish Medical Bulletin. 34 (6): 289–97. PMID 3325233.